Cidara Therapeutics 미래 성장

Future 기준 확인 1/6

Cidara Therapeutics은 연간 수입과 매출이 각각 2.5%와 17.5% 증가할 것으로 예상되고 EPS는 연간 32.7%만큼 증가할 것으로 예상됩니다.

주요 정보

2.5%

수익 성장률

32.7%

EPS 성장률

Biotechs 수익 성장	27.6%
매출 성장률	17.5%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	13 Dec 2024

최근 미래 성장 업데이트

Recent updates

We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

Sep 28

Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop

Apr 17

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year

Mar 25

Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M

Aug 09

Industry Analysts Just Made A Captivating Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Revenue Forecasts

Dec 17

Rainbows and Unicorns: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Just Became A Lot More Optimistic

Aug 17

Is Cidara Therapeutics (NASDAQ:CDTX) Weighed On By Its Debt Load?

Aug 04

Cidara Therapeutics: Rezafungin Data Could Bring Value

Jul 20

수익 및 매출 성장 예측

NasdaqCM:CDTX - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	N/A	-122	-114	-69	5
12/31/2025	N/A	-101	-102	-59	5
12/31/2024	6	-155	-145	-133	5
9/30/2024	45	-124	-160	-160	N/A
6/30/2024	54	-112	-125	-125	N/A
3/31/2024	59	-24	-19	-18	N/A
12/31/2023	64	-23	-23	-22	N/A
9/30/2023	31	-34	-31	-31	N/A
6/30/2023	62	-18	-1	-1	N/A
3/31/2023	64	-22	-16	-16	N/A
12/31/2022	64	-34	-29	-28	N/A
9/30/2022	61	-33	-22	-22	N/A
6/30/2022	28	-63	-62	-62	N/A
3/31/2022	54	-44	-47	-47	N/A
12/31/2021	50	-42	-25	-25	N/A
9/30/2021	46	-47	-21	-21	N/A
6/30/2021	41	-47	-24	-24	N/A
3/31/2021	12	-74	-41	-41	N/A
12/31/2020	12	-75	-55	-54	N/A
9/30/2020	10	-67	-59	-58	N/A
6/30/2020	27	-47	-28	-28	N/A
3/31/2020	23	-42	-27	-27	N/A
12/31/2019	21	-41	-29	-29	N/A
9/30/2019	19	-39	-27	-27	N/A
6/30/2019	N/A	-56	-57	-56	N/A
3/31/2019	N/A	-69	-59	-59	N/A
12/31/2018	N/A	-69	-57	-57	N/A
9/30/2018	N/A	-70	-53	-53	N/A
6/30/2018	N/A	-69	N/A	-54	N/A
3/31/2018	N/A	-59	N/A	-50	N/A
12/31/2017	N/A	-56	N/A	-50	N/A
9/30/2017	N/A	-57	N/A	-52	N/A
6/30/2017	N/A	-57	N/A	-46	N/A
3/31/2017	N/A	-52	N/A	-43	N/A
12/31/2016	N/A	-48	N/A	-40	N/A
9/30/2016	N/A	-44	N/A	-35	N/A
6/30/2016	N/A	-41	N/A	-34	N/A
3/31/2016	N/A	-35	N/A	-31	N/A
12/31/2015	N/A	-32	N/A	-26	N/A
9/30/2015	N/A	-27	N/A	-22	N/A
6/30/2015	N/A	-21	N/A	-18	N/A
3/31/2015	N/A	-18	N/A	-13	N/A
12/31/2014	N/A	-12	N/A	-8	N/A
9/30/2014	N/A	-8	N/A	-5	N/A

애널리스트 미래 성장 예측

수입 대 저축률: CDTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: CDTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: CDTX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: CDTX 의 수익(연간 17.5% ) US 시장( 9.2% 보다 빠르게 성장할 것으로 예상됩니다. 9.2% 연간).

고성장 수익: CDTX 의 수익(연간 17.5% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: CDTX 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/26 13:18
장 마감 주가	2024/12/26 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Cidara Therapeutics, Inc. 14 애널리스트 중 5 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Timothy Chiang	BTIG
Chiara Russo	Cantor Fitzgerald & Co.
Louise Chen	Cantor Fitzgerald & Co.

Cidara Therapeutics 미래 성장

Future 기준 확인 1/6

주요 정보

최근 미래 성장 업데이트

Consensus estimates of losses per share improve by 21%

Forecast to breakeven in 2025

Consensus revenue estimates fall by 30%

Forecast to breakeven in 2025

Consensus revenue estimates increase by 85%

Forecast to breakeven in 2023

Recent updates

Cidara Therapeutics, Inc. Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza

Cidara Therapeutics, Inc. announced that it expects to receive $104.999685 million in funding from a group of investors

Cidara Therapeutics, Inc. Announces the Appointment of Scientific Advisory Board Members

Cidara Therapeutics, Inc. Announces Reduction in Workforce to Focus on Planned Clinical Development of CD388

Cidara Therapeutics Appoints Jim Beitel as Chief Business Officer

Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 3000E Value Index

Cidara Therapeutics, Inc., Annual General Meeting, Jul 18, 2024

Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules

Napp Pharmaceutical Group Ltd. acquired All assets and rights related to REZZAYO of Cidara Therapeutics, Inc. (NasdaqCM:CDTX).

Cidara Therapeutics, Inc. announced that it expects to receive $240 million in funding from RA Capital Management, L.P., Canaan Management, Inc., BVF Partners L.P. and other investors

Cidara Therapeutics, Inc. announced delayed annual 10-K filing

Cidara Therapeutics, Inc. Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults

Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China

Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id

Cidara Therapeutics Requests a Hearing Before the Nasdaq Hearings Panel

Consensus estimates of losses per share improve by 21%

New minor risk - Profitability

Forecast to breakeven in 2025

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cidara Therapeutics and Mundipharma Receive Positive CHMP Opinion for Rezafungin for the Treatment of Invasive Candidiasis in Adults

Cidara Therapeutics, Inc. Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023

We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

New major risk - Financial position

Cidara Therapeutics, Inc. Appoints Nicole Davarpanah as Senior Vice President of Translational Research and Development

Consensus revenue estimates fall by 30%

New minor risk - Profitability

Forecast to breakeven in 2025

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Cidara Therapeutics Provides Update on REZZAYO™ (Rezafungin for Injection)

Cidara Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B

New minor risk - Market cap size

Cidara Therapeutics, Inc. to Present Highlights from Its Ongoing Preclinical Studies of CD421 as Well as the Development of Its Novel Drug-Fc Conjugates from Cidara’s Cloudbreak® Platform

Consensus revenue estimates increase by 85%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year

Full year 2022 earnings: EPS misses analyst expectations

Forecast to breakeven in 2023

We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely

Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Price target decreased to US$5.50

Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from Its Cloudbreak Platform

Cidara Therapeutics, Inc. and Melinta Therapeutics, LLC Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet

High number of new directors

Consensus revenue estimates increase by 67%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cidara Therapeutics Attends Hearing Before the Nasdaq Hearings Panel and Presents Plan to Regain Compliance with the Nasdaq Capital Market

Cidara spikes on $11M milestone payment from partner Mundipharma

Cidara Therapeutics, Inc. Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Cidara Therapeutics Announces Initiation of Phase 2A Human Viral Challenge Trial to Evaluate Cd388 for Universal Prevention of Influenza

Cidara begins dosing of antiviral CD388 in trial for preventing influenza

Cidara Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 53%

Second quarter 2022 earnings: EPS exceeds analyst expectations

Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M

Cidara Therapeutics, Inc. Submits New Drug Application to the U.S. Food and Drug Administration for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$5.67

High number of new directors

Mundipharma and Cidara Therapeutics Announces First Presentation of Results from Global Phase 3 ReSTORE Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrating its Positive Efficacy and Safety Profile

Cidara Therapeutics, Inc. Announces Executive Changes

Cidara Therapeutics, Inc. Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of CD388 in Development for Universal Prevention and Treatment of Seasonal and Pandemic Influenza

Consensus revenue estimates increase by 44%

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Medicines and Healthcare Products Regulatory Agency in the UK Grants Mundipharma and Cidara Therapeutics Inc.'s Rezafungin Promising Innovative Medicine Designation

Cidara Therapeutics, Inc. Announces FDA Acceptance of its Investigational New Drug Application for CD388 for Universal Prevention and Treatment of Influenza

Price target increased to US$6.25